Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Main Street Capital Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Main Street Capital Corporation trades at $58.73 (market cap $5.52B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.4× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.39% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MAIN | |
|---|---|---|
Market Cap | $29.60B | $5.52B |
Sector | Health | Financials |
52-Week High | $491.22 | $67.54 |
52-Week Low | $205.48 | $49.63 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 5.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Main Street Capital (MAIN) trades at $58.51, slightly below the consensus price target of $56.67, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings of $0.97 per share missed expectations. Recent dividend announcements and portfolio appreciation highlight MAIN's income-focused strategy in the BDC sector.
MAIN presents a stable income opportunity with consistent dividends, but faces headwinds from higher expenses impacting recent earnings. The stock's current valuation at 11.85x P/E appears reasonable, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in the private credit market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
